港股异动 | 基石药业-B(02616)午后涨超6% 获纳入港股通标的证券名单国际大行相继看好公司发展前景

智通财经09-08

智通财经APP获悉，基石药业-B(02616)午后涨超6%，截至发稿，涨5.27%，报6.385港元，成交额8209.73万港元。消息面上，基石药业-B发布公告，本公司发行并于香港联合交易所有限公司上市的股份获纳入港股通标的证券名单，自2026年9月7日起生效。本公司核心资产 PD‑1/VEGF/CTLA‑4三特异性抗体CS2009的全球I/II期临床试验正高效推进，预计将于2026年底前启动首批...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2665426603?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-08 13:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2665426603","market":"us","top_or_hot":-1,"title":"港股异动 | 基石药业-B(02616)午后涨超6% 获纳入港股通标的证券名单 国际大行相继看好公司发展前景","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，基石药业-B(02616)午后涨超6%，截至发稿，涨5.27%，报6.385港元，成交额8209.73万港元。消息面上，基石药业-B发布公告，本公司发行并于香港联合交易所有限公司上市的股份获纳入港股通标的证券名单，自2026年9月7日起生效。本公司核心资产 PD‑1/VEGF/CTLA‑4三特异性抗体CS2009的全球I/II期临床试验正高效推进，预计将于2026年底前启动首批...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1493223.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 基石药业-B(02616)午后涨超6% 获纳入港股通标的证券名单 国际大行相继看好公司发展前景</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 基石药业-B(02616)午后涨超6% 获纳入港股通标的证券名单 国际大行相继看好公司发展前景\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-08 13:41 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1493223.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，基石药业-B(02616)午后涨超6%，截至发稿，涨5.27%，报6.385港元，成交额8209.73万港元。消息面上，基石药业-B发布公告，本公司发行并于香港联合交易所有限公司上市的股份获纳入港股通标的证券名单，自2026年9月7日起生效。本公司核心资产 PD‑1/VEGF/CTLA‑4三特异性抗体CS2009的全球I/II期临床试验正高效推进，预计将于2026年底前启动首批...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1493223.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KCAI","symbol_name":"KraneShares China Alpha Index ETF","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1493223.html","article_id":"2665426603","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2665426603","pubTimestamp":1788846117,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，基石药业-B午后涨超6%，截至发稿，涨5.27%，报6.385港元，成交额8209.73万港元。消息面上，基石药业-B发布公告，本公司发行并于香港联合交易所有限公司上市的股份获纳入港股通标的证券名单，自2026年9月7日起生效。其中，高盛预计，未来6至12个月将是基石药业关键催化剂密集兑现的阶段。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"161027":"证券","KCAI":"KraneShares China Alpha Index ETF","BK1574":"生物医药B类股","VXUS":"国际股票ETF-Vanguard","FLHK":"Franklin FTSE Hong Kong ETF","BK4588":"碎股","02616":"基石药业-B","BK1161":"生物科技","BK4585":"ETF&股票定投概念"},"translate_title":"Hong Kong Stocks in Focus | CStone Pharmaceuticals-B (02616) rose over 6% in the afternoon after being included in the list of securities eligible for the Hong Kong Stock Connect program; major international banks are optimistic about the company's development prospects.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1.5,"KCAI":1.5,"FLHK":1.5,"VXUS":1.5,"02616":1.5},"content_text":"智通财经APP获悉，基石药业-B(02616)午后涨超6%，截至发稿，涨5.27%，报6.385港元，成交额8209.73万港元。消息面上，基石药业-B发布公告，本公司发行并于香港联合交易所有限公司上市的股份获纳入港股通标的证券名单，自2026年9月7日起生效。本公司核心资产 PD‑1/VEGF/CTLA‑4三特异性抗体CS2009的全球I/II期临床试验正高效推进，预计将于2026年底前启动首批全球III期注册临床试验。本公司自研EGFR/HER3双特异性ADC CS5007的全球I期临床试验也已启动，将在中国与澳大利亚同步开展。值得关注的是，近日，国际大行杰富瑞、高盛相继发布研报看好基石药业-B发展前景，核心逻辑均指向公司核心自研管线CS2009持续改善的临床数据与BD出海机遇、年底前即将密集落地的全球III期多区域临床(MRCT)试验，以及公司上半年高质量经营业绩。其中，高盛预计，未来6至12个月将是基石药业关键催化剂密集兑现的阶段。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2665426603","isCrawlerRequest":true}

港股异动 | 基石药业-B(02616)午后涨超6% 获纳入港股通标的证券名单 国际大行相继看好公司发展前景

精彩评论

港股异动 | 基石药业-B(02616)午后涨超6% 获纳入港股通标的证券名单国际大行相继看好公司发展前景